|
Feb 24
|
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Feb 20
|
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
|
|
Feb 12
|
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
|
|
Feb 12
|
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
|
|
Feb 12
|
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
|
|
Feb 12
|
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
|
|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 3
|
Neumora Stock Hits Record Low on Depression Drug Study Failure
|
|
Jan 2
|
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
|
|
Jan 2
|
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
|
|
Jan 2
|
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
|
|
Dec 5
|
GSK Expands Vaccine Collaboration With Zhifei in China
|
|
Dec 4
|
JANX Stock Hits Record High on Prostate Cancer Study Data
|
|
Dec 3
|
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
|
|
Oct 2
|
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
|
|
Sep 27
|
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
|
|
Sep 23
|
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
|